Daiichi Sankyo

AZ, Daiichi Sankyo get early okay for DS-8201, now named Enhertu

The US approval sparks a $125m payment to Daiichi Sankyo from AZ – the first milestone payment in the alliance. ... Sales of Enhertu in the US will be booked by Daiichi Sankyo with AZ claiming a share of gross profits.

EMA backs adjuvant use of Roche’s breast cancer ADC Kadcyla

Among the rivals is Daiichi Sankyo and AstraZeneca’s  trastuzumab deruxtecan (DS-8201), another ADC currently under regulatory review for patients with advanced HER2-positive breast cancer that have failed Kadcyla

AZ, Daiichi Sankyo strengthen case for HER2 candidate

Will rival Roche's HER2 franchise if approved. AstraZeneca’s big bet on a Daiichi Sankyo-developed HER2-targeting antibody-drug conjugate looks like its about to pay off, after delivering ... AZ and Daiichi Sankyo are looking at a possible approval for

Seattle Genetics moves to dismiss ADC lawsuit with Daiichi Sankyo

US-based biotech is arguing the legal action is improper. Seattle Genetics has asked a court to dismiss a lawsuit brought a few weeks ago by Japan’s Daiichi Sankyo centring ... The two companies previously collaborated on ADC drug development between

Daiichi files lawsuit with Seattle over ADCs, including AZ-partnered DS-8201

Daiichi said today that Seattle Genetics is “claiming certain intellectual property rights related to Daiichi Sankyo’s ADC products”, a stance which it insists is “without merit”. ... The original agreement between the companies cover ADCs

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]